Mergers & Acquisitions
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Track global pharma M&A deals, divestitures, and partnerships. Gain critical intelligence for strategic investment and business development in life sciences.
Showing 1–11 of 11 articles
Quick answer
NovaPharmaNews Mergers & Acquisitions hub for EMA covers 11 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EU Pharma Package exclusivity timelines: what innovators can do now
China Becomes Big Pharma's Essential R&D Partner
Lilly to Spotlight Growing Hematology Portfolio at 2026 EHA Annual Meeting: Key Data and Strategic Implications
Owkin and AstraZeneca Enhance AI Collaboration for Drug Research
European Navenibart Deal: A Strategic Win for BioCryst's Rare Disease Portfolio
SERB Pharmaceuticals Acquires European and MENA Rights to Idefirix® (imlifidase) from Hansa Biopharma AB
Viridian Partners with WuXi Bio for Eye Drug Supply Amid FDA Decision
Gilead's $140M Deal with Yuhan: Implications for Pharma
Roche's Licensing Deal for Xofluza: Implications and Insights
Purdue Pharma Shutdown: $7.4B Deal Ends OxyContin Maker's Operations
Advanced Bifurcation Systems Acquires Svelte Medical Systems in Major Coronary Stent Deal
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.